Health.

“The weight-loss product marketed as "Jillian Michaels' Jelly Lean" does not work for weight loss.”

Consumers should not expect weight loss from anything sold as 'Jillian Michaels' Jelly Lean.' Jillian Michaels says the product is not real or endorsed by her, BBB records describe scam complaints, and the gummies reportedly sent to buyers contain ingredients with weak or no reliable evidence for meaningful weight loss. The main caveat is that no authentic, standardized product exists to test directly.

“Drinking hydrogen-rich water improves kidney function in people with chronic kidney disease.”

Early research suggests possible benefits, but current evidence does not show that drinking hydrogen-rich water reliably improves kidney function in people with chronic kidney disease. The strongest reviews describe the human evidence as limited and preliminary. Much of the positive evidence comes from animal studies, very small trials, or dialysis settings that do not prove benefit for the broader CKD population.

“Traditional Chinese Medicine practitioners assess a person's health status by using pulse diagnosis, tongue observation, and physical examination to identify patterns of imbalance.”

The statement matches mainstream descriptions of TCM diagnosis. Authoritative sources describe pulse reading, tongue observation, and palpation/physical examination as standard tools used to identify syndromes or patterns of imbalance. The main caveat is that classical TCM diagnosis usually also includes questioning and listening/smelling, so the claim is accurate but not complete.

“In acupuncture assessment for migraine, practitioners evaluate a patient's body balance using methods such as pulse reading, tongue observation, and physical examination to identify patterns of imbalance.”

The claim accurately describes standard TCM-style acupuncture assessment for migraine. Major medical and NIH-linked sources describe acupuncturists using pulse reading, tongue observation, and physical examination to identify patterns of imbalance before treatment. The main caveat is that these steps are part of traditional diagnostic practice and are not always standardized or detailed in migraine guidelines or clinical trials.

“After an initial course of acupuncture for migraine management, maintenance acupuncture sessions are typically done monthly or as needed.”

The evidence does not support monthly or as-needed maintenance acupuncture as a typical post-course schedule for migraine. Stronger sources describe the initial treatment course and possible durable benefit, but do not identify a standard maintenance frequency. Some clinics recommend monthly or flexible booster visits, yet those suggestions are individualized practice advice rather than an established norm in the medical literature.

“Acupuncture sessions for migraine treatment typically last 45–60 minutes, including consultation time.”

The core claim is supported: reputable migraine guidance says acupuncture visits commonly run about an hour and include consultation or assessment time. Shorter durations in many studies usually refer only to needle-retention time, not the full appointment. The main caveat is that “45–60 minutes” is a narrower range than the best sources directly establish, and real-world visit length varies by clinic and visit type.

“Acupuncture is used both for migraine prevention (reducing future migraine attack frequency) and for relief during an active migraine attack.”

Available evidence supports both parts of the claim. Acupuncture is well studied as a preventive option for migraine, with multiple systematic reviews showing reduced attack frequency. It has also been used during active migraine attacks in trials and some clinical settings, although the acute-use evidence is much smaller and it is not a standard first-line abortive treatment.

“Only two of seven triptan medicines available globally are publicly funded in New Zealand: sumatriptan and rizatriptan.”

Current New Zealand evidence supports the claim. PHARMAC’s schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.

“In New Zealand, funded sumatriptan and funded rizatriptan are available at the standard prescription co-payment of about NZ$5 for people with a Community Services Card.”

The evidence does not support this statement. Official New Zealand sources indicate Community Services Card holders generally pay no co-payment for fully subsidised prescriptions from publicly funded or approved providers, not “about NZ$5.” In addition, the materials provided directly support funded sumatriptan but do not directly verify funded rizatriptan.

“Consuming caffeine via energy drinks is worse for health than consuming an equivalent amount of caffeine via coffee.”

The evidence indicates that energy drinks generally cause more adverse acute cardiovascular effects than the same amount of caffeine from coffee. Randomized trials show larger changes in blood pressure and electrical heart measures after energy drinks, including one direct caffeine-matched coffee comparison. But the claim is broader than the evidence: most studies are short-term, use surrogate markers, and do not prove worse overall or long-term health outcomes in every circumstance.

“A recommended initial course of 6–10 sessions at clinics in Auckland, New Zealand, typically totals NZ$480–NZ$1,400 before any maintenance sessions.”

The stated total is not a reliable typical range for Auckland clinics as a whole. Better-sourced Auckland therapy pricing shows many mainstream professional services already cost about NZ$1,350–NZ$1,680 for 6 sessions, exceeding the claim's upper limit. The range can fit some lower-cost wellness, counselling, or cosmetic packages, but the claim omits that crucial distinction and overstates how typical those prices are.

“Sessions at clinics in Auckland, New Zealand, typically cost NZ$80–NZ$140 each.”

The claim overstates what a typical Auckland clinic visit costs. Many routine GP and general clinic appointments, especially for enrolled patients, are commonly below NZ$80, often in roughly the NZ$26–NZ$65 range. NZ$80–NZ$140 is more characteristic of higher-priced subsets such as urgent care, non-enrolled or visitor consults, and some private or specialized services, not clinic sessions overall.

“Fruit remains in the human stomach for only about 15 minutes after being eaten.”

The 15-minute figure is not supported by clinical evidence. Whole fruit is a structured, fiber-containing food, not a clear liquid, and standard medical sources describe stomach emptying for solids in hours rather than minutes. Even unusually fast estimates for some fruits are generally above 15 minutes and do not justify a broad claim about all fruit.

“Kūmarahou (Pomaderris kumeraho) does not kill bacteria and is not an antibacterial agent.”

The evidence does not support a blanket denial of antibacterial activity. Peer-reviewed lab studies found kūmarahou extracts inhibited at least two human pathogens, S. aureus and B. cereus, which qualifies as antibacterial activity under standard testing. Evidence for broad bactericidal effects or clinical benefit is more limited, but that caveat does not rescue the claim’s absolute wording.

“Triptans are taken during a migraine attack, not before or after it.”

The evidence shows triptans are primarily acute medicines used to stop or reduce an ongoing migraine attack, not preventive drugs taken in advance or treatments used after the attack has ended. The main caveat is that some guidelines allow them during aura, which can occur before headache pain but is still part of the migraine attack.

“Kūmarahou does not have universally agreed dosage guidelines.”

The evidence supports the claim. Authoritative regulatory and scientific sources do not show any globally or broadly standardized dosage guideline for kūmarahou, while available dosing advice varies across traditional, practitioner, and commercial sources. Some guidance exists, but it is local and non-universal rather than a single agreed standard.

“The gut-brain axis is a real biological communication system between the gastrointestinal tract and the brain.”

The core claim is well supported by mainstream biomedical literature. The gut-brain axis refers to real, bidirectional communication between the gastrointestinal tract and the brain via neural, hormonal, immune, and microbial pathways. What remains unsettled are some specific mechanisms and clinical implications, not the existence of gut-brain communication itself.

“The human gut microbiome produces enough neurotransmitters to directly influence human personality traits and temperament.”

The evidence does not support a direct microbiome-to-personality effect through microbial neurotransmitters. Gut microbes do make neuroactive chemicals, but these generally do not cross into the brain in amounts that would directly shape personality or temperament. Current human research mainly suggests indirect gut-brain signaling and possible links to mood or symptoms, not proven direct control of stable personality traits.

“Most digestive enzymes produced by the small-intestinal wall are bound to the apical (brush-border) cell membrane of intestinal epithelial cells rather than being freely secreted into the intestinal lumen.”

The evidence supports the core claim: small-intestinal digestive enzymes are predominantly brush-border membrane proteins, especially disaccharidases and many peptidases. A minor fraction can be shed into the lumen, and not every enzyme in intestinal cells is brush-border bound, but those caveats do not overturn the main point.

“The study described in PubMed Central article PMC12952596 was a randomized clinical trial with a sample of 212 adults.”

The study is well-supported as a randomized clinical trial in adult cancer patients, but the specific claim that it had a sample of 212 adults is not directly confirmed in the evidence provided. Multiple authoritative records identify the article and its trial design. However, none of the cited excerpts actually quote the participant count, and planned enrollment may differ from the final analyzed sample.